Vitamin Shoppe, Inc (VSI) Price Target Cut to $6.00
Vitamin Shoppe, Inc (NYSE:VSI) had its target price cut by equities researchers at Barclays PLC from $13.00 to $6.00 in a research report issued to clients and investors on Thursday. The firm presently has an “equal weight” rating on the specialty retailer’s stock. Barclays PLC’s price target would suggest a potential downside of 1.64% from the company’s current price.
Other research analysts have also recently issued reports about the company. Morgan Stanley upgraded Vitamin Shoppe from an “underweight” rating to an “equal weight” rating and set a $14.00 price target for the company in a research report on Thursday, May 11th. Zacks Investment Research upgraded Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine cut Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Gabelli cut Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, BidaskClub cut Vitamin Shoppe from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company. Vitamin Shoppe currently has a consensus rating of “Hold” and an average price target of $18.43.
Vitamin Shoppe (NYSE:VSI) remained flat at $6.10 during midday trading on Thursday. 1,423,545 shares of the stock traded hands. Vitamin Shoppe has a one year low of $6.00 and a one year high of $28.56. The firm’s 50 day moving average is $10.69 and its 200-day moving average is $16.09. The company has a market capitalization of $141.29 million, a PE ratio of 7.85 and a beta of 0.68.
Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings results on Wednesday, August 9th. The specialty retailer reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.39 by $0.16. The company had revenue of $304.84 million for the quarter, compared to analysts’ expectations of $314.74 million. Vitamin Shoppe had a net margin of 1.43% and a return on equity of 9.35%. The firm’s revenue was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.55 earnings per share. Equities research analysts anticipate that Vitamin Shoppe will post $1.24 EPS for the current year.
Several hedge funds have recently bought and sold shares of VSI. Comerica Bank boosted its stake in Vitamin Shoppe by 37.8% in the first quarter. Comerica Bank now owns 35,339 shares of the specialty retailer’s stock worth $689,000 after buying an additional 9,685 shares during the period. Norges Bank acquired a new stake in Vitamin Shoppe during the fourth quarter worth approximately $6,444,000. First Trust Advisors LP acquired a new stake in Vitamin Shoppe during the first quarter worth approximately $549,000. LSV Asset Management boosted its stake in Vitamin Shoppe by 109.4% in the first quarter. LSV Asset Management now owns 76,648 shares of the specialty retailer’s stock worth $1,544,000 after buying an additional 40,048 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Vitamin Shoppe by 3.7% in the first quarter. Principal Financial Group Inc. now owns 181,564 shares of the specialty retailer’s stock worth $3,659,000 after buying an additional 6,408 shares during the period.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.